EdiGene是一家生物技术公司，其使命是将前沿的基因组编辑技术转化为治疗遗传病和癌症的新疗法，并将其转化为创新的解决方案，以推进药物发现。我们利用我们的专有平台来开发针对一系列疾病的基因编辑疗法，并进行高通量的基因组筛选，以便能够在生物学环境中剖析功能性大数据。
Location: China, Chongqing, Changping
Employees: 51-200
Total raised: $67M
Founded date: 2015
Investors 6
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | Emerging T... | etpvc.com |
| - | 3H Health ... | 3hhinvestm... |
| - | IDG Capita... | en.idgcapi... |
| - | Oceanpine ... | oceanpinec... |
| - | WI Harper ... | wiharper.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.10.2020 | Series B | $67M | - |
Mentions in press and media 8
| Date | Title | Description |
| 22.04.2021 | China’s genome editing startup EdiGene nets $62m in Series B+ round | Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business... |
| 15.10.2020 | Beijing-based Edigene raises $67 million to develop gene-editing therapies | |
| 14.10.2020 | Chinese biotech firm EdiGene nabs $67m from Sequoia, IDG, others | Premium Chinese novel gene-editing platform EdiGene Inc has raised 450 million yuan ($67 million) in its Series B round funding led by Chinese healthcare industry focused private equity fund 3H Health, according to a company statement on Oc... |
| 13.10.2020 | EdiGene Raises Approx. USD 67M in Series B Financing | EdiGene, Inc., a Beijing, China-based developer of genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, completed an RMB 450 million (approximately USD 67 million) Series B f... |
| 11.04.2019 | Japanese biotech firm EdiGENE raises $14.4m in Series B | Premium EdiGENE, a Japanese biotechnology firm that develops CRISPR-based therapies, has raised ¥1.6 billion ($14.4 million) in its Series B funding round led by UTokyo Innovation Platform, the University of Tokyo’s investment arm for innov... |
| 09.08.2018 | Chinese biotech EdiGene raises $15m pre-Series B led by Lilly Asia Ventures | Premium Beijing-based biotech company EdiGene Inc – that uses genome editing technologies for novel therapeutics and advanced drug discovery solutions – has raised about $15 million in a pre-Series B financing round led by Lilly Asia Ventur... |
| 08.08.2018 | EdiGene Raises $15 Million in Series pre-B Financing | BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced the succe... |
| 08.08.2018 | Genome Editing Biotech Company EdiGene Raises $15M in Series Pre-B Round | EdiGene Inc., a Beijing, China-based genome editing biotech company, raised approximately $15M in a Series pre-B financing. The round was led by new investor Lilly Asia Ventures (LAV) with participation from new investor Huagai Capital and ... |